key: cord-0829671-2czdud7f authors: Kohli-Pamnani, Anita; Zapata, Kristen; Gibson, Tiffany; Kwittken, Pamela L. title: COVID-19 Vaccine Hypersensitivity Evaluated with Vaccine and Excipients Allergy Skin Testing date: 2021-09-03 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2021.08.417 sha: fb9d0a64b38c6cb1f9d0da8774e5d4abcf78f63e doc_id: 829671 cord_uid: 2czdud7f nan 19 vaccine excipients, specifically polyethylene glycol (PEG), polysorbate 80 and polysorbate 20. Utilizing this algorithm, and skin testing with COVID-19 mRNA vaccine leftover from vial overfill, we report findings in a case series of 39 patients referred to an Allergy and Immunology practice for possible COVID-19 vaccine hypersensitivity January through May 2021. Expanded skin testing for COVID-19 vaccine excipients was performed as previously published. 2 Additionally, percutaneous and intradermal skin tests (1:10 dilution and full strength both for pricks and intradermals) with Moderna/Pfizer COVID-19 vaccines were completed. We recorded whether premedication was used and analyzed available laboratory data (serum tryptase, SC5B-9, CBC with differential). Premedication could consist of H1/H2 blockers and/leukotriene antagonists. An example regimen was Cetirizine 20 mg, Famotidine 40 mg and Monteleukast 10 mg daily starting three days before vaccine. Patient outcome, or vaccine tolerance was assessed through follow up and/chart review. Patient characteristics and atopic conditions are shown, Table 1 . 77% (n=30) of patients were referred for reactions to COVID-19 mRNA vaccine. The remaining 23% (n=9) were referred for other high risk history for potential reaction to vaccine. The most common clinical presentation (Table I. ) was urticaria and/or angioedema, immediate (within 4 hours) in 36% of patients (n=14) and delayed (beyond 4 hours) in 28% of patients (n=11). Overall, 46% of reactions were immediate (n=18), mean time to occurrence was 32 minutes. 31% of reactions were delayed (n=12), average time to manifestation was 3.8 days. Such designation was not applicable in 23% The skin test positive patients also tolerated subsequent vaccine. 95% of patients (n=37) tolerated their succeeding COVID-19 vaccine without serious allergic reaction. 92% (n=36) have received two doses of COVID-19 vaccines. One patient pre screened due to severe chronic idiopathic urticaria and angioedema elected to receive Janssen vaccine. Most of the patients with mild hypersensitivity or non-immediate symptoms safely completed the two dose vaccine series. To our knowledge, we report the first large series of COVID-19 vaccine hypersensitivity referrals in a private Allergy and Immunology practice. Since private practices did not have access to full vials of vaccine for administration during the period of study, there was not an option of graded challenge. Some patients with more severe symptoms of immediate hypersensitivity reactions with or without positive skin tests to vaccine may have benefitted from graded dose challenge or desensitization. 8 Our findings, though, suggest a simpler paradigm in that most individuals with prior reactions would be able to receive their subsequent COVID-19 vaccine dose with or without premedication, or by treating through mild to moderate allergic symptoms. A limitation was that non-irritant skin test concentrations of COVID-19 vaccine have not yet been established. We did skin test control individuals on our health care team, and skin tests were negative, suggesting positive immediate intradermal skin tests at 1:10 and full strength were likely non-irritant. A study of 131 patients with idiopathic anaphylaxis found negative pre screening percutaneous tests for COVID-19 mRNA vaccines and excipients including trometamol (buffer in Moderna vaccine associated with anaphylaxis to gadolinium contrast). 9 However, intradermal skin testing was not performed. Our findings did not demonstrate an IgE mediated pathogenesis for immediate type COVID-19 vaccine hypersensitivity, given vastly negative skin tests. There may be non-specific mast cell histamine release which can be countered with premedication or treating through the reactions. Other researchers espoused that theory based on their clinical findings and experience with premedication for possible allergic reactions to COVID-19 mRNA vaccine. 6 We could not confirm whether CARPA (complement activation related pseudoallergy) was a putative mechanism but found no evidence of abnormal complement levels in the few patients where SC5B-9 was obtained. A systematic review cites overall utility of skin testing for COVID-19 vaccine and excipients to be of uncertain diagnostic value. 10 Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach COVID-19 vaccination in patients with reported allergic reactions: updated evidence and suggested approach Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: early report Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports Safety of new mRNA vaccines against COVID-19 in severely allergic patients The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach Table 1. Patient Characteristics, COVID-19 Vaccine Hypersensitivity Age, Mean (SD), y Pfizer 19 (47.5), Janssen 2 (5) a Patients On Baseline Antihistamine, No. (%) 14 (36) Patients On Baseline Monteleukast The authors thank Laurel Shader MD for provision of leftover COVID-19 mRNA vaccines from vial overfill.